Georgia's Online Cancer Information Center


back

Uterine Cancer Clinical Trials in Georgia

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.
Cancer Type = Uterine Cancer
Cancer Type = Uterine Cancer
NCI ID Cancer Type Trial Name
There are currently 8 active Uterine Cancer clinical trials in Georgia.
NCI ID Cancer Type Trial Name
1.
A Study of ACR-368 in Ovarian Carcinoma, Endometrial Adenocarcinoma, and Urothelial Carcinoma
Cancer Type
Ovarian Cancer, Solid Tumor, Unknown Primary, Uterine Cancer
NCT ID
NCT05548296
Protocol IDs
ACR-368-201 (GOG 3082)
NCI-2022-10629
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
2.
NCORP Trial
Abemaciclib and Letrozole to Treat Endometrial Cancer
Cancer Type
Unknown Primary, Uterine Cancer
NCT ID
NCT04393285
Protocol IDs
GOG-3039
NCI-2020-08167
Treatment Sites (1)
Nancy N. and J.C. Lewis Cancer Research Pavilion at St. Joseph Candler
Savannah
Alaina Underberg
912-819-5778
3.
Evaluation of Sexual Toxicities in Women After Pelvic Radiotherapy
Cancer Type
Anal Cancer, Cervical Cancer, Colon/Rectal Cancer, Gynecologic Cancers, Solid Tumor, Uterine Cancer
NCT ID
NCT05394428
Protocol IDs
20-2369
NCI-2022-05850
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
4.
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
Cancer Type
Brain Tumor, Colon/Rectal Cancer, Liver Cancer / Hepatoblastoma, Melanoma, Neuroblastoma, Non-Hodgkin Lymphoma, Ovarian Cancer, Sarcoma, Uterine Cancer, Wilms Tumor
NCT ID
NCT04851119
Protocol IDs
PEPN2011
PEPN2011
NCI-2021-02852
5.
Testing Nivolumab with or without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma
Cancer Type
Uterine Cancer
NCT ID
NCT05112601
Protocol IDs
NRG-GY025
NRG-GY025
NCI-2021-11881
Treatment Sites (1)
Augusta University Medical Center
Augusta
Carol Terry
706-721-4430
6.
Testing Olaparib and Temozolomide versus the Usual Treatment for Uterine Leiomyosarcoma after Chemotherapy Has Stopped Working
Cancer Type
Sarcoma, Unknown Primary, Uterine Cancer
NCT ID
NCT05432791
Protocol IDs
A092104
A092104
NCI-2022-05065
NCT05432791
7.
Testing the Addition of the AKT Inhibitor, Ipatasertib, to Treatment with the Hormonal Agent Megestrol Acetate for Recurrent or Metastatic Endometrial Cancers
Cancer Type
Unknown Primary, Uterine Cancer
NCT ID
NCT05538897
Protocol IDs
NRG-GY028
NRG-GY028
NCI-2022-07505
Treatment Sites (1)
Augusta University Medical Center
Augusta
Carol Terry
706-721-4430
8.
Testing the Addition of Trastuzumab or Trastuzumab/Pertuzumab to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma
Cancer Type
Uterine Cancer
NCT ID
NCT05256225
Protocol IDs
NRG-GY026
NRG-GY026
NCI-2022-01540
Treatment Sites (3)
Bluffton Campus at St. Joseph's/Candler
Bluffton
St. Joseph's /Candler Health System, INC
Savannah
Stephanie J. Reyes
912-819-5723
St. Joseph's /Candler Health System, INC
Savannah
About Us Research Resources & Education Screening & Genetics Clinical Trials & Providers Cancer Navigators Survivorship Media, News & Events Contact Us Donate Take Our Survey Link to Us

Research

Screening & Genetics

Clinical Trials & Providers

Survivorship

About Georgia CORE

Education & Resources

Media, News & Events

Patient Navigation

Georgia CORE

 

Advancing Cancer Care through Partnerships and Innovation

Georgia CORE is a statewide nonprofit that leverages partnerships and innovation to attract more clinical trials, increase research, and promote education and early detection to improve cancer care for Georgians in rural, urban, and suburban communities across the state.